Presentations Focus on the Implications of Metabolic Acidosis and CKD
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has authored or sponsored 12 presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2020 being held virtually October 22-25, 2020. Data to be presented at multiple sessions at the meeting will expand the breadth of information about the implications of metabolic acidosis and CKD. All Tricida presentations will be available on Thursday, October 22, 2020 at 10:00am ET. Session and presentation titles are listed below:
Session Title: CKD Risk Factors: Diet, Environment, Lifestyle
|
Title: |
Relationship Between Metabolic Acidosis and Chronic Kidney Disease Progression is Evident Across United States Racial and Ethnic Groups |
|
Author: |
N. Tangri et al. |
|
ePoster #: |
PO0468 |
|
|
|
|
Title: |
Metabolic Acidosis is Associated with Chronic Kidney Disease Progression: A Longitudinal Analysis of >100,000 United States Community-Based Patients |
|
Author: |
V. Mathur et al. |
|
ePoster #: |
PO0469 |
|
|
|
|
Title: |
Metabolic Acidosis and Progression to Renal Replacement Therapy (Encore Presentation) |
|
Author: |
V. Mathur et al. |
|
ePoster #: |
PO0467 |
Session Title: Advances in Geriatric Nephrology
|
Title: |
Effects of Veverimer on Serum Bicarbonate and Physical Function in Elderly Patients with Metabolic Acidosis in Chronic Kidney Disease |
|
Author: |
D. Wesson et al. |
|
ePoster #: |
PO1685 |
|
|
|
|
Title: |
Correlation Between Patient-Reported Physical Limitation and Objective Physical Performance on the Repeated Chair Stand Test Among Patients with Non-Dialysis Dependent Chronic Kidney Disease and Metabolic Acidosis |
|
Author: |
V. Mathur et al. |
|
ePoster #: |
PO1687 |
Session Title: CVD, BP, and Kidney Diseases: Exploring the Link
|
Title: |
No Adverse Effects of Veverimer on Volume Status or Blood Pressure in Patients with Chronic Kidney Disease and Metabolic Acidosis |
|
Author: |
D. Wesson et al. |
|
ePoster #: |
PO2116 |
Session Title: Women’s Health and Kidney Diseases
|
Title: |
Effects of Veverimer on Serum Bicarbonate and Physical Function in Women with Chronic Kidney Disease: A Subgroup Analysis from a Randomized Controlled Trial |
|
Author: |
V. Mathur et al. |
|
Session: |
Women’s Health and Kidney Diseases |
|
ePoster #: |
PO2612 |
Session Title: Diabetic Kidney Disease: Clinical – 2
|
Title: |
Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and Chronic Kidney Disease: Subgroup Analysis from a Randomized Trial (Encore presentation) |
|
Author: |
D. Wesson et al. |
|
ePoster #: |
PO1033 |
Session Title: Fluid, Electrolyte, and Acid-Base Disorders: Clinical – 2
|
Title: |
Metabolic Acidosis is a Predictive Factor for All-Cause Mortality in Patients with Chronic Kidney Disease (Encore presentation) |
|
Author: |
N. Tangri et al. |
|
ePoster #: |
PO1483 |
Session Title: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)
|
Title: |
Action of Veverimer on Gastrointestinal Acid Binding is Not Affected by Omeprazole |
|
Author: |
D. Parsell et al. |
|
ePoster #: |
PO2374 |
|
|
|
|
Title: |
Evaluation of Veverimer Drug Interaction Potential (Encore presentation) |
|
Author: |
J. Shao et al. |
|
ePoster #: |
PO2373 |
Session Title: Informational Posters
|
Title: |
Understanding the Long-Term Impact of Metabolic Acidosis in Chronic Kidney Disease: Design of the ULTIMA-CKD Patient Registry |
|
Author: |
V. Mathur et al. |
|
ePoster #: |
INFO16 |
About Metabolic Acidosis
Metabolic acidosis is a chronic condition commonly caused by CKD and is believed to accelerate the progression of kidney deterioration. Metabolic acidosis is estimated to pose a health risk to approximately three million patients with CKD in the United States and currently there are no U.S. Food and Drug Administration (FDA)-approved chronic therapies for treating metabolic acidosis. Metabolic acidosis is a serious condition in which the body has accumulated too much acid and occurs when a patient’s kidneys can no longer excrete sufficient acid or produce enough bicarbonate to balance acid production. The prevalence and severity of metabolic acidosis in people with CKD progressively rises as kidney function declines. As a chronic condition, metabolic acidosis is associated with an increased risk of CKD progression and death. It is also associated with an increased risk of muscle wasting and loss of bone density.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting the VALOR-CKD clinical trial to evaluate the efficacy and safety of veverimer in delaying CKD progression in subjects with metabolic acidosis. There are no FDA-approved treatments for chronic metabolic acidosis.
For more information about Tricida, please visit www.Tricida.com.
Contacts
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com